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Background aims. Macrophages have complex roles in the liver. The aim of this study was to compare proﬁles of humanmonocyte-
derivedmacrophages between controls and cirrhotic patients, to determinewhether chronic inﬂammation affects precursor number
or thephenotype,with the eventual aim todevelop a cell therapy for cirrhosis.Methods. Infusion of human macrophages in a murine
liver ﬁbrosis model demonstrated a decrease in markers of liver injury (alanine transaminase, bilirubin, aspartate transaminase)
and ﬁbrosis (transforming growth factor-b, a-smooth muscle actin, phosphatidylserine receptor) and an increase in markers of
liver regeneration (matrix metalloproteinases [MMP]-9, MMP-12 and TNF-related weak inducer of apoptosis). CD14þ
monocytes were then isolated from controls. Monocytes were matured into macrophages for 7 days using a Good Manufacturing
Practiceecompatible technique. Results. There was no signiﬁcant difference between the mean number of CD14þ monocytes
isolated from cirrhotic patients (n ¼ 9) and controls (n ¼ 10); 2.8  SEM 0.54  108 and 2.5  0.56  108, respectively. The
mean yield of mature macrophages cultured was also not signiﬁcantly different between cirrhotic patients and controls (0.9  108
 0.38  108, with more than 90% viability and 0.65  108  0.16  108, respectively. Maturation to macrophages resulted in
up-regulation of a number of genes (MMP-9, CCL2, interleukin [IL]-10 and TNF-related weak inducer of apoptosis). A
cytokine and chemokine polymerase chain reaction array, comparing the control and cirrhotic macrophages, revealed no sta-
tistically signiﬁcant differences. Conclusions. Macrophages can be differentiated from cirrhotic patients’ apheresis-derived CD14
monocytes and develop the same pro-resolution phenotype as control macrophages, indicating their suitability for clinical therapy.Introduction
Macrophages are a heterogeneous population of
cells with diverse roles within the liver, including
phagocytosis, maintaining immune tolerance and
both promotion and resolution of inﬂammation and
ﬁbrosis through activation of hepatic stellate cells/
production of cytokines and degradation of the
extracellular matrix, respectively [1e4]. They are
also involved in the livers’ regenerative response after
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http://dx.doi.org/10.1016/j.jcyt.2015.07.016Hepatic macrophages can arise either from
bone marrow (BM)-derived monocytes or from self-
renewing endogenous cells in the liver, termed Kupffer
cells [7]. Although an oversimpliﬁcation given their
complex function, two distinct in vitro macrophage
phenotypes have been described; M1 (pro-inﬂamma-
tory) and M2 (anti-inﬂammatory) [8]. M1s are associ-
ated with Th-1 CD4 T cells and induced by interleukin
(IL-12, interferon-g and lipopolysaccharide (LPS) in
response to liver injury. M2s are linked to Th-2 CD4 Tne, SCRM Building, The University of Edinburgh, Edinburgh bioQuarter,
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currently widespread use of at least four deﬁnitions of
macrophage activation (M1/M2, alternative/classic
activation,“regulatory”macrophages and subdivisions),
and there is a requirement for common terminology
and consistent use of markers across the literature [10].
Macrophages can both promote ﬁbrogenesis by
activating the pro-ﬁbrotic cytokine transforming
growth factor (TGF)-b [11] and by stimulating
myoﬁbroblast proliferation by platelet-derived growth
factor (PDGF), IL-1b and tumor necrosis factor-a
[12]. They are also critical for ﬁbrosis resolution
because they provide a rich source of the scar-
degrading matrix metalloproteinases (MMPs) [13].
They produce factors such as MMP-9, which pro-
mote hepatic stellate cell apoptosis, needed for scar
resolution [14]. They also phagocytose cellular debris,
which removes potential pro-inﬂammatory signals [3].
It is known that there are more circulating
monocytes in patients with chronic liver disease than
in healthy controls, and there is a close association
with this and disease progression [15]. There is also
T-cell activation in cirrhosis accompanied by an
increase in circulating anti-inﬂammatory and pro-
inﬂammatory cytokines but attenuated cytokine
production in T cells [15,16].
Previous work by our group demonstrated that
administration of mature murine macrophages
(and not undifferentiated monocytes) into a CCl4-
induced murine liver injury model results in early
chemokine up-regulation, leading to hepatic recruit-
ment of endogenous macrophages, an increase in
anti-inﬂammatory cytokines, decrease in hepatic
myoﬁbroblasts and overall improvement in clinically
relevant parameters such as albumin [17].
Further work by our group [3] identiﬁed a
“restorative macrophage” in the mouse that undergoes
a functional switch during liver injury from an inﬂam-
matory Ly-6Chi monocyte/macrophage subset to a Ly-
6Clo subset that is capable of resolvingﬁbrosis.Of note,
continued inﬁltration by Ly-6Chi macrophages after
the cessation of injury inhibited ﬁbrosis regression,
postulating that endogenous macrophages aid ﬁbrosis
resolution and inﬁltrating macrophages worsen it.
Published human data in patients with cirrhosis is
lacking. It is known that endogenous macrophages
are signiﬁcantly increased [11,18], and it has been
assessed that these Kupffer cells are constantly
replenished by inﬁltrating monocytes [11,19],
although this is contentious and some data contend
that monocytes do not contribute to the resident pool
[20e22]. Macrophages also stimulate hepatic pro-
genitor cell activation in uninjured and injured liver
with macrophage-derived TNF-related weak inducer
of apoptosis (TWEAK) stimulating progenitor cell
expansion via the FN14 receptor [6,23].Cell therapy offers an alternative therapeutic avenue
to increase the survival of patients with liver disease, for
which there is no speciﬁc therapy. BM is considered a
promising source of cells for liver regenerative therapy
because the cells are readily obtained and manipulated
[24]. During the past decade, a subset of clinical trials in
cirrhotic patients has shown the safety, feasibility and
improvement in liver function and regeneration after
BM cell administration via multiple administration
routes [24e30]. Although this has shown that in prin-
ciple, phase 2 autologous stem cell trials can be con-
ducted incirrhoticpatients, ourpreclinicalwork suggests
that cultured and matured macrophages are likely to be
more potent anti-ﬁbrotic and pro-regenerative cells than
unmanipulated hematopoietic stem cells [17]. Further-
more, if this cell therapy can be developed as an anti-
ﬁbrotic approach, then wider applications may be
envisaged for conditions where macrophages have been
shown to have a role in the resolution of tissue ﬁbrosis or
the promotion of tissue regeneration for example pul-
monary [31], renal [32,33] and skin ﬁbrosis [34].
Although a different, non-autologous macrophage
product with differing indications and underlying
aetiology, there are a subset of phase II trials utilizing
macrophages with potential therapeutic beneﬁt
including the ongoing ONE study M-reg trial
(clinicaltrials.gov, identiﬁer NCT02085629) in which
donor-derived regulatory macrophages (differentiated
in the presence of interferon-g) are intravenously
infused to living-donor renal transplant recipients with
the primary outcome measure being the incidence of
biopsy conﬁrmed acute rejection. Other phase II trials
include a randomized controlled trial in which an
injection of autologous incubated macrophages were
given into the caudal boundary in acute, complete
spinal cord injury [35], and an open label, multi-
center, randomized trial in which patients with
non-muscle invasive bladder cancer were given in-
stillations of intravesical autologous macrophage cell
therapy [36]. There has also been a phase II study in
which patients with malignant pleural mesothelioma
were given an intra-pleural infusion of activated
macrophages [37]. The product in all these trials was
well tolerated, although efﬁcacy is uncertain.
The aim of this cohort study was to determine the
feasibility of generating clinical-grademacrophages with
a phenotype and function, which reﬂects previously
characterized therapeutic macrophages in our model
of cirrhotic disease with a view to macrophage therapy.Methods
Methods for murine experiments
NOD CB17 Prkdc/SCID mice were supplied by
Charles River and housed in individually ventilated
1606 J. K. Moore et al.cages in a sterile animal facility with a 12-hour
dark/light cycle and free access to food and water.
All procedures were performed in accordance with
UK Home Ofﬁce guidelines (Animals [Scientiﬁc
Procedures] Act 1986). Chronic liver ﬁbrosis was
induced in adult female mice over a 10-week period
by twice weekly intraperitoneal injections of carbon
tetrachloride (CCl4) dissolved in sterile olive oil at
a concentration of 0.1 mL/kg for ﬁrst 4 weeks
increasing to 0.5 mL/kg for the remaining 6 weeks.
One day after the 12th CCl4 injection (6 weeks), mice
were randomly allocated to receive either cell (n ¼ 8)
or control (n ¼ 7) medium injections via the spleen.
The intra-splenic route was selected because it is
anatomically easier than portal vein injection yet
would still ensure maximal cell delivery compared to
tail vein injection [38]. Cells were injected while mice
were under isoﬂuorane-induced anaesthesia. The
macrophages used were isolated from an apheresis
product from a healthy volunteer and matured for
7 days in culture in the presence of 100 ng/mL
macrophage colony-stimulating factor (M-CSF).
Macrophages were suspended in sterile saline at
a density of 5  107 cells/mL and 0.1 mL was injected
via a 29-gauge needle. CCl4 administration continued
for an additional 4 weeks. All mice were culled
4 weeks after the last macrophage/vehicle injection.Immunohistochemistry
Sirius red staining (BDH Laboratory Supplies) of
formalin-ﬁxed tissue sections was performed to
identify collagen. Three-micrometer sections of
formalin-ﬁxed tissue were used for immunostaining
of a-smooth muscle actin (a-SMA; Sigma) using a
biotinylated anti-mouse secondary antibody (Vector)
and F4/80 (Abcam) using a biotinylated ant-rat
secondary antibody (Vector), then visualized using
3,30-diaminobenzidine (Dako) then counterstained
with Harris’s hematoxylin.Assessment of tissue sections
Stained slides were blinded and a minimum of 20
serial, non-overlapping ﬁelds were photographed
at 100 magniﬁcation (Nikon Eclipse E600). For
a-SMA, F480 and sirius red assessment, the per-
centage staining of the total ﬁeld was measured using
image analysis software (Adobe Photoshop, NIS
elements).Quantiﬁcation of messenger RNA levels by real-time
reverse-transcription polymerase chain reaction
RNA was extracted from whole liver tissue using
RNA extraction kits (Qiagen) according to themanufacturer’s instructions. Complementary DNA
was generated from 1 mg of RNA using the Super-
script II kit (Invitrogen). Primers for TGF-b,
COL1, MMP-9 and mouse TWEAK were pur-
chased from Qiagen. A predesigned, validated
eukaryotic 18S primer/probe set (Applied Bio-
systems) was used for internal control. Quantitative
real-time polymerase chain reaction (qPCR) was
performed using Express SYBR Green or TaqMan
Express qPCR Supermix (Invitrogen). All reactions
were performed in triplicate. Levels are expressed as
dCT relative to glyceraldehyde 3-phosphate
dehydrogenase.Liver function
Albumin, alanine transaminase (ALT), aspartate
transaminase (AST), alkaline phosphatase (ALP)
and bilirubin levels were measured in serum using
commercial kits (albumin, bilirubin, ALT: Alpha
Laboratories Ltd.; AST, ALP; Randox Laboratories)
adapted for use on a Cobas Fara centrifugal analyser
(Roche Diagnostics).
As these initial murine experiments demonstrated
human monocyte-derived macrophages (HMDMs)
decreased these markers of liver injury and ﬁbrosis
and increased markers of regeneration we then pro-
ceeded to determine the possibility of generating
human clinical-grade macrophages with a phenotype
and function that would reﬂect the therapeutic
macrophages in our model of cirrhotic disease with
a view to macrophage therapy.Methods for translational human study
Ethical approval was granted by the South East
Scotland Research Ethics Committee 02, and use of
buffy coats was covered by Scottish National Blood
Transfusion Service (SNBTS) Sample Governance
(13e12/14e02). Informed consent for apheresis
donation was obtained in accordance with the Hel-
sinki Declaration.
Initial phenotyping studies were performed on
monocytes isolated from normal donor buffy coats.
In addition, 10 healthy volunteer controls were
recruited between August 2011 and March 2013 to
demonstrate initial feasibility and then 11 patients
with cirrhosis attending the Royal Inﬁrmary of
Edinburgh were recruited between January 2013 and
October 2013.
Eligibility criteria included patients between 18
and 75 years with cirrhosis being deﬁned by any
one of the following: previous liver biopsy conﬁrm-
ing histological features of cirrhosis, transient
elastography (Fibroscan) >18 kPa and/or clinical
and radiological features that in the opinion of
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cirrhosis.
Exclusion criteria included refusal or inability to
give informed consent to participate in the study,
patients with viral hepatitis, average alcohol ingestion
>21 units/week (male)/>14 units/week (female), as-
cites not well controlled with diuretic therapy in the
preceding 3 months, encephalopathy requiring hos-
pitalization for treatment in the past 3 months, portal
hypertensive bleeding in the preceding 3 months,
hepatocellular carcinoma, other cancer within the
previous 5 years, previous liver transplant or
currently on the waiting list, the presence of a clini-
cally relevant acute illness that may compromise the
patient’s safe participation, and pregnancy and/or
breastfeeding.
Patients initially attended for a “screening” visit
to ensure trial eligibility and safety of participation.
A full medical history, examination, vital signs,
electrocardiograph and baseline blood tests to
include a full blood count, urea and electrolytes, liver
function tests and prothrombin time, were under-
taken. Veins were also assessed to ensure suitability
to undergo apheresis in which circulating monocytes
would be peripherally extracted.
Healthy volunteers also attended a “screening”
visit to ensure safety of participation as detailed
above. In addition, 50 mL of peripheral blood was
obtained from the healthy volunteers to ensure that
the mononuclear cells would be comparable to
those in the more favorable apheresis product in
which it would be possible to obtain much higher
yields.
Within 1 month from the initial screening visit,
participants attended for apheresis.Isolation of CD14 monocytes from peripheral blood from
healthy volunteers
Mononuclear cells were separated from whole blood
obtained by venepuncture from healthy volunteers or
from buffy coats and were separated by density
centrifugation using Histopaque (Life Technologies
Ltd). CD14 positive monocytes were isolated
from the mononuclear cell fraction using Clin-
iMACS CD14 reagent (to ensure compatibility with
clinical-grade selections) and LS separation mag-
netic columns (Miltenyi Biotec). Brieﬂy, cells were
re-suspended to appropriate concentration in
phosphate-buffered saline (PBS) plus ethyl-
enediaminetetraacetic acid (2.5 mmol/L) and human
serum albumin (PEA buffer), incubated with Clin-
imacs CD14 beads, then washed and passed through
an LS column. After washing, the puriﬁed mono-
cytes were eluted from the column, washed and
re-suspended in medium for culture.Isolation of mononuclear cells from apheresis
A single procedure was performed using the Optia
apheresis system and a sterile collection technique.
A standard program for collection of mononuclear
cells (MNCs) was employed. Between 2 and 2.5 blood
volumes were processed where circumstances
permitted. CD14 cells were isolated from the resultant
product using CliniMACS CD14 reagent and an
autoMACS separation apparatus (Miltenyi). Brieﬂy,
the apheresis product was diluted 1 in 5 with PBS,
centrifuged then washed again with PBS. Cells were
re-suspended inAutoMacs buffer (Miltenyi) and 0.5%
fetal bovine solution (FBS) then counted and re-
suspended to appropriate concentration and incu-
batedwith clinical gradeCD14microbeads.Cellswere
washed as before and re-suspended at manufacturer’s
recommended concentration for separation on auto-
MACS (Miltenyi). Cell suspension was passed
through a pre-separation ﬁlter before being applied to
the autoMACS and the number of separations per-
formed was determined by the cell concentration as
recommended by the manufacturer. The resultant
monocytes were washed and re-suspended in medium
for culture. The purity of the separation was assessed
using a panel of antibodies against human leucocytes.Culture of CD14 monocytes
CD14þve monocytes were cultured under low
adhesion conditions in six-well plates (Corning) for
buffy coat monocytes orMACSGoodManufacturing
Practice (GMP) 100 mL expansion bags (Miltenyi
Biotec) for all apheresis samples at a density of 2 106
cells/mL in the presence of 100 ng/mL human
recombinant M-CSF (Miltenyi) in a humidiﬁed at-
mosphere at 37C (95%O2/5%CO2). Initial cultures
were carried out in Iscove’sModiﬁedEagle’sMedium
supplemented with 10% FBS from a validated GMP-
compliant source (Life Technologies Ltd). Further
experiments were carried out in serum-free AIMV
medium (Invitrogen) to comply with GMP re-
quirements. In all experiments a media change was
performed on days 3 and 5. Low-adhesion plates were
used because these best mimic the conditions in the
expansion bags. Furthermore, if normal tissue culture
plastic had been used, the macrophages would readily
attach to the plastic, making it difﬁcult to remove
them without either mechanical disruption or enzy-
matic treatment, which could result in increased cell
death and an altered macrophage phenotype.Flow cytometry
Cell surface expression of leucocyte markers in
freshly isolated and day 7 matured cells was carried
1608 J. K. Moore et al.out by incubating cells with speciﬁc antibodies (ﬁnal
dilution 1:100). The following antibodies were used
CD14-Alexa ﬂuor 700 (M5E2; Biolegend) or PE
(Miltenyi), CD16-Paciﬁc blue (3G8; Biolegend),
CD66b-FITC (80H3; AbD Serotech), CD209-
perCPcy5.5 (9E9A8; Biolegend), CD163-PE
(GHI/61; Biolegend), 25F9-eFluor 660 (eBio-
sciences), CD206-PE/Cy7 or FITC (15-2; Bio-
legend), CD11b perCPcy5.5 (ICRF44; Biolegend),
CD93 APC (VIMD2; Biolegend), CD105 FITC
(43A3; Biolegend), CD19-PE (HIB19; E-bio-
sciences), CD45 Paciﬁc-blue or Brilliant Violet
421(HI30; Biolegend, Miltenyi), HLA-DR alexa
ﬂuor 700 (L243; Biolegend), CCR2 (K036C2; Bio-
legend), and CD169-PE (7-239; Miltenyi). Cells
were incubated on ice for 20 min, and then cells were
washed in ﬂuorescence-activated cell sorter buffer
(PBS) containing 0.5% bovine serum albumin. Buffy
coat monocytes and macrophages were gated to
exclude debris, doublets and dead cells using DRAQ7
dead cell discriminator (Biolegend) and analyzed on a
Canto II ﬂow cytometer. Apheresis cells were ﬁxed in
2% formalin before analysis on an LSRFortessa Flow
cytometer (Beckton Dickenson). Data were analyzed
using Flowjo software (Treestar).
Phagocytosis was determined by incubating
human macrophages with pHrodo Red Staphylo-
coccus aureus Bioparticles (Invitrogen). Cells were
incubated for 30 min at 37C and then ﬁxed in
formalin, or for 1 hour then washed with ice-cold
PBS-ethylenediaminetetraacetic acid and examined
by ﬂuorescence microscopy and ﬂow cytometry.RNAextraction and quantitative reverse transcriptase-PCR
RNA was extracted from day 0 and day 7 CD14þve
healthy volunteer and cirrhotic cells for transcript
analysis by qPCR. RNA was extracted from cells
using RNA extraction kits (Qiagen) according to the
manufacturer’s instructions. Complementary DNA
was generated from 1 mg of RNA using the Super-
script II kit (Invitrogen). Predesigned, validated
primer sets for MMP-9, CCL2, IL-10, CCL3, TNF,
CXCL2 and TWEAK were purchased from Qiagen.
A predesigned, validated eukaryotic 18S primer/
probe set (Applied Biosystems) was used for internal
control. qPCR was performed using Express SYBR
Green or qPCR Supermix (Invitrogen). All reactions
were performed in triplicate. Levels are expressed
relative to 18S.Pathway array
A qPCR RT2 proﬁler array (PAHS-150ZG-4 human
chemokine and cytokine array) was purchased
from SABiosystems and was used as per themanufacturers protocol (n ¼ 4 patients, n ¼ 4
healthy volunteers at day 7).Statistical methods
Data values are presented as mean and standard
error of the mean, SEM, or percentages unless
otherwise stated. Statistical analysis was performed
using SPSS (SPSS 19.0) and Graphpad Prism
(GraphPad Software Inc.). Flow cytometric, yield
and gene data between day 0 and day 7 was
compared using Student’s t-test. Data were routinely
tested for normality using the Shapiro-Wilk test and
for outliers using box plots. Results were considered
statistically signiﬁcant when P < 0.05.Results
HMDMs improve murine liver ﬁbrosis and function
Our previous work has shown that infusions of
mature mouse macrophages improve liver function
and ﬁbrosis in mice during CCl4-induced liver
ﬁbrosis [17] and stimulate liver regenerative path-
ways [6]. We therefore wanted to assess the effect of
mature human macrophages on CCl4-induced liver
ﬁbrosis in mice. We used the NOD CB17 PrkdcSCID
immunocompromised strain to test the efﬁcacy of
human macrophages. CD14þ monocytes were iso-
lated from an apheresis product from a healthy
volunteer and matured into macrophages for 7 days
in the presence of M-CSF as described in Methods.
Maturation was conﬁrmed by expression of the
mature macrophage marker 25F9 and the absence of
the monocyte marker CD93 and of other leukocyte
markers for neutrophils, T and B cells. On week 6 of
a 10-week CCl4-induced injury protocol, 5  106
cells were delivered intrasplenically. The livers of
mice treated with human macrophages showed
signiﬁcantly reduced ﬁbrosis as measured by Sirius
red (P ¼ 0.0002) and a trend to reduced myoﬁbro-
blast activation as measured by alpha-SMA quanti-
ﬁcation (P ¼ 0.59) and expression of the proﬁbrotic
gene TGF-b (P ¼ 0.13; see Figure 1A).
The MMP family and TWEAK are critical reg-
ulatory components that result in the degradation of
the extracellular matrix, key to the resolution of
ﬁbrosis [6]. Mice receiving HMDMs had non-
signiﬁcant trends to increased gene expression of
MMP-12 (P ¼ 0.31), MMP-9 (P ¼ 0.61) and
signiﬁcantly increased TWEAK (P ¼ 0.03). Mice
receiving HMDMs had signiﬁcant improvement in
ALT (P ¼ 0.03), AST (P ¼ 0.02) and improvement
in bilirubin (P ¼ 0.29) in the treated group
(Figure 1C). However, the same marked improve-
ment was not seen in ALP.
Figure 1. (A) Quantitation of collagen (picrosirius red staining [PSR]), myoﬁbroblast activation (alpha-SMA) and macrophage recruitment
(F480) in ﬁbrotic mouse liver following HMDM injection, showing HMDMs decrease liver ﬁbrosis, with no effect on macrophage
recruitment. As measured quantitatively by PSR and alphaSMA and by gene expression/glyceraldehyde 3-phosphate dehydrogenase by
TGF-b (B) HMDMs show down-regulation of TGF-b and up-regulation of MMP-12, MMP-9 and TWEAK and improvement in liver
function tests (C) in NOD/SCID mice (n ¼ 8) compared with control injection (n ¼ 7; mean and SEM, *P < 0.05).
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clinical histological endpoint) is signiﬁcantly
improved by macrophage therapy, some
inﬂammation-related indices such as MMP-9 and
MMP-12 were not signiﬁcantly changed. This may
reﬂect the necessary use of immunocompromised
mice and therefore lack of the ampliﬁed effect seen in
previous studies, which were mouse-mouse studies
[6,17] (Figure 1B). This ampliﬁed effect was medi-
ated by recruitment of host macrophages and in-
ﬂammatory cells, via injected macrophages
chemokine secretion, to the scar areas in the immu-
nocompetent mice and increased the effect of the
single cell injection. There was no signiﬁcant differ-
ence in the macrophage F480 staining 4 weeks after
injection with either HMDMs or control medium
(Figure 1A and 2).Baseline human data
A total of 10 healthy volunteers and 11 patients with
cirrhosis underwent screening. All healthy volunteers
completed the study. One patient failed screening as
the patient’s veins were not deemed suitable for
apheresis, and one patient underwent apheresis, but
it was not possible to separate the CD14þ cells suf-
ﬁciently, most likely because the patient had a high
granulocyte count. Thus nine patients completed the
study. Because this was exploratory with a devel-
oping methodology, paired gene data between base-
line and day 7 was obtained for cirrhotic patients andhealthy volunteers but not statistically compared
between the two groups.
Of the nine patients who completed the study,
seven patients were men (77%), with a median age of
66 years (interquartile range [IQR] 63e69). Five
patients had cirrhosis secondary to alcoholic liver
disease (ALD; 55%), two secondary to both ALD
and non-alcoholic fatty liver disease (NAFLD; 22%),
one secondary to NAFLD (11%), and 1 cryptogenic
(11%). At time of screening, all patients had Childs
[39] grade A liver disease with a median Model for
End-Stage Liver Disease [40] prognostic score of 8.3
(IQR 6.8e9.8). Of the seven patients in whom
alcohol was an etiological factor, all patients had
been abstinent for at least 6 months apart from one
who drank eight units per day. There was no statis-
tical difference between this patient and the others.
All patients tolerated apheresis well with no
adverse events other than mild transient symptoms of
hypocalcaemia (well recognized to occur with
apheresis secondary to the citrate) quickly corrected
with oral calcium. This was corroborated by a follow-
up telephone call to the patient 1-month post-
procedure.
With a median time of 9.5 months (IQR 4e14
months) since apheresis, no patients had experienced
any liver-related complications. One patient had
been diagnosed with type II diabetes mellitus and
had a permanent pacemaker ﬁtted. These events
occurred 9 months after apheresis and were not
assessed to be related.
Figure 2. (A) Photomicrograph showing picrosirius red staining for hepatic collagens in CCl4-treated mice 4 weeks after injection with
HMDMs or control medium, original magniﬁcation 100. (B) Photomicrograph showing F480 staining 4 weeks after injection with
HMDMs or control medium, original magniﬁcation 200.
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macrophages
Preliminary characterization of monocytes and
macrophages from normal blood donors was per-
formed using a panel of lineage and functional
markers to determine changes between day 0 mono-
cytes and day 7 macrophages. The mature macro-
phage marker 25F9 was signiﬁcantly increased on
day 7 macrophages, and there was a concomitant
signiﬁcant rise in markers associated with phagocy-
tosis and tissue repair (CD163, CD169 and CD206)
[41,42]. There was also a signiﬁcant decrease in the
level of the inﬂammatory cytokine receptor CCR2
(Figure 3). This phenotypic proﬁle is indicative of
disease resolution macrophages identiﬁed in the
previous models of liver disease and in otherpathologies [43,44]. This led us to determine
whether this phenotype was consistent in macro-
phages generated from cirrhotic patients.Yields
The mean number of CD14þ monocytes isolated
was 2.8  SEM 0.54  108 from cirrhotic patients,
n ¼ 9 (18%  SEM 5% CD14þ as a total of the
MNCs processed) compared with 2.5  0.6  108,
(8%  2% CD14þ) for healthy volunteers, n ¼ 10
(t ¼ 0.38, P ¼ 0.7, 95% conﬁdence interval
[CI] 1.4 to 2.0). There was also no signiﬁcant
difference in the mean yield of mature macrophages
cultured from cirrhotic patients and healthy volun-
teers (0.9  108  0.4  108 (48%  9% as a total of
Figure 3. Quantitative analysis of macrophage phenotype in normal blood donors. Analysis of mean ﬂuorescence index (MFI) of lineage
(A and B), chemokine receptor (CCR) 2 (C) and phagocytosis markers (DeF) expressed on day 0 monocytes and day 7 after macrophage
induction with M-CSF. All markers demonstrated signiﬁcant increases (A, B, DeF) or decreases (C) in MFI at day 7. Data represent the
means and SEM from 4 to 8 donors for each marker (*P < 0.05).
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in cirrhotic patients and 0.65  108  0.16  108
(47%  11%) for healthy volunteers (t ¼ 0.43 with
Welch’s correction as unequal variances, P ¼ 0.69,
95% CI 0.82 to 1.23). The day 7 macrophages had
less than 5% apoptotic cells as measured by annexin
V staining (Supplementary Figure 1).
The aim of the study was to validate a GMP-
compliant protocol for the generation of macro-
phages from cirrhotic patients with a view to utilizing
these cells as a cellular therapy. Therefore, we
modiﬁed our protocol to incorporate a culture pro-
tocol that was animal-free and used a serum-free
deﬁned media (AIMV Invitrogen). There was no
signiﬁcant deterioration in yields between the AIMV
media and serum-containing media (n ¼ 2 healthy
volunteers, 3.75  106 CD14þ cultured, 37.5%
AIMV versus 2.29  106 CD14þ cultured FBS,
22.9% and 5.5  106 CD14þ cultured, 18.3%
AIMV versus 8.75  106 CD14þ cultured, 29.2%
FBS (t ¼ 0.27, P ¼ 0.81, 95% CI 13.5 to 15.29).Characterisation of macrophages from healthy volunteers
and cirrhotics
Figure 4 shows the ﬂow cytometry characterization of
CD14þ monocytes and day 7 matured macrophages
isolated from peripheral blood and apheresis from
a healthy volunteer. Matured cells were larger andmore granular than monocytes. Following 5e7 days
in culture in low-adhesion expansion bags in the
presence of M-CSF, the cells from both peripheral
blood and apheresis had lost expression of the
monocyte speciﬁc marker CD93 and gained expres-
sion of the mature macrophage marker 25F9 [45].
The cells exhibited coexpression of the pan-leucocyte
marker CD45 and the myeloid marker CD11b with
intermediate expression of CD16 and CD209 and low
expression of the B-cell (CD19) and neutrophil
(CD66b) markers. There was no signiﬁcant difference
between peripheral blood and apheresis-derived
monocytes. Over 5 to 7 days in culture, cells
increased expression of CD16 and 25F9 and reduced
expression of the monocyte marker CD93.
The macrophages matured from the cirrhotic
patients exhibited a similar cell surface marker proﬁle
as the healthy volunteers at day 0 and after 7 days in
culture again with co-expression of CD45 and
CD11b, intermediate expression of CD16 and
CD209 (a dendritic cell marker but also a marker of
the anti-inﬂammatoryelike macrophage phenotype)
and low expression of CD19 and CD66b (Figure 5).
They also exhibited the same phagocytic features as
would be seen with mature control macrophages
(Figure 5C). All cells expressed differentiation
markers consistent with an M2-like (anti-inﬂamma-
tory) phenotype with high expression of CD206,
CD163 and Mac-2.
Figure 4. Characterization of monocyte-derived macrophages from apheresis from healthy volunteers. (A) Apheresis derived CD14
monocytes were isolated as described in Methods (n ¼ 10) and cultured for 7 days in M-CSF-containing media with 10% fetal calf serum.
(B) Forward/side scatter properties and CD93/25F9 expression in day 0 and day 7 matured cells. Marker expression is presented as %
positivity compared with isotype controls. (C) Surface marker expression in CD14 monocytes isolated from peripheral blood (n ¼ 5) or
apheresis (n ¼ 10) matured for 5 or 7 days with M-CSF. Where relevant, data are presented as mean and SEM.
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showed that maturation resulted in an increase in
expression of several MMPs and chemokines and
cytokines. There were signiﬁcant differences in
MMP-9 (P ¼ 0.04) and IL-10 (P ¼ 0.04) in the
genes in the cirrhotic patients between day 0 and day
7 and signiﬁcant differences in MMP-9 (P ¼ 0.03),
CCL2 (P ¼ 0.02), IL-10 (P ¼ 0.006) and TWEAK
(P ¼ 0.02) in the controls (Figure 6). Up-regulation
of TWEAK and IL-10 would be consistent with an
M2 anti-inﬂammatory phenotype.
We also conducted an extensive human cytokine
and chemokine array (Supplementary Figure 2)
comparing the healthy volunteer and cirrhoticpatients’ macrophages at day 7. This revealed
up-regulation from cirrhotic patients relative to HVs
of IL-7, CCL17, CXCL12, CCL18 and CXCL and
down-regulation of BMP6, but none were statisti-
cally signiﬁcant (Figure 7).Discussion
We have shown for the ﬁrst time that it is possible to
differentiate CD14 positive monocytes from cirrhotic
patients into macrophages in a GMP compliant envi-
ronment, which demonstrate the same phenotypic
proﬁle as healthy controls. The macrophages show
Figure 5. Characterization of monocytes and macrophages isolated from apheresis from healthy volunteer (n ¼ 10) and cirrhotic patients
(n ¼ 9). (A) Surface marker expression in CD14 monocytes. (B) Surface marker expression relative to isotype control in day 7 matured
macrophages. (C) Representative immunoﬂuorescent image of mature control macrophages phagocytosing PhRhodamine-labeled Staph-
ylococcus aureus (red) particles (red) nuclei are labelled with 40,6-diamidino-2-phenylindole (blue). Where relevant, data are presented as
mean and SEM.
Phenotypic and functional characterization of macrophages 1613a signiﬁcant increase in the mature macrophage
marker 25F9; a signiﬁcant rise in the phagocytosis and
repair markers CD163, CD169 and CD206; and
decrease in the inﬂammatory cytokine receptor CCR2.
Similar cell surface marker proﬁles were
demonstrated, differentiation markers of the M2Figure 6. Gene change between day 0 apheresis derived monocytes and
M-CSF in healthy volunteers (n ¼ 5) and cirrhotic patients (n ¼ 8), (n(anti-inﬂammatory) phenotype were exhibited and
yields were comparable between healthy volunteer
and cirrhotic patients.
There was marked up-regulation in key cytokines
in the ﬁbrosis and regeneration pathways of the liver
such as MMP-9 and IL-10, but the qPCR arrayafter 7 days of differentiation with AIMV media and 100 ng/mL
s, nonsigniﬁcant, *P < 0.05, mean and SEM).
Figure 7. Scatter plot of RT2 Proﬁler cytokine and chemokine
PCR array of apheresis-derived macrophages from healthy
volunteers (n ¼ 4) and cirrhotic patients (n ¼ 4). Red circles show
genes up-regulated 2-fold from cirrhotic patients relative
to volunteers, green circles down-regulated 2-fold, all
nonsigniﬁcant.
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phages did not demonstrate a signiﬁcant difference
in the proﬁles. It is known that monocytes in
cirrhotic patients exhibit different cytokine produc-
tion patterns to healthy volunteers [15,16] but our
data suggest that the monocyte-derived macrophages
do not; this is important to establish before potential
macrophage cellular therapy.
Although macrophages play a key contributory
role in liver ﬁbrosis by releasing pro-ﬁbrogenic cy-
tokines, promoting the survival of activated hepatic
stellate cells (HSCs) [46] and promoting HSC
migration through chemokines such as CCL2 [47],
they also promote ﬁbrosis resolution through
enhanced extracellular matrix degradation via
increased MMP expression [3]. “Pro-resolution”
macrophages contribute to this resolution by
contributing to the killing of HSCs—for example,
through the expression of TNF-related apoptosis-
inducing ligand [47].
Our earlier in vivo work, mouse BM-derived
macrophages (and not undifferentiated monocytes)
were infused in a murine model of liver ﬁbrosis and
resulted in improvement in clinically relevant pa-
rameters such as albumin and a reduction in ﬁbro-
genesis [17], demonstrating their therapeutic
potential. This same therapeutic potential of
HMDMs has been shown with our in vivo work
presented here with signiﬁcant improvements in the
main histological endpoint: ﬁbrosis and markers of
liver function. The trends in MMP levels may have
reached statistical signiﬁcance if an intact recipient
immune system were present. Previous studies
in immunocompetent mice showed a signiﬁcantcellular ampliﬁcation mediated by injected cell-host
cell recruitment to the hepatic scar areas [17].
Although a dose escalation study would be neces-
sary, given 5  106 seem to be therapeutic and
well tolerated in a 20 g mouse, it could be expected
that 1  109 macrophages may be effective in
humans, allowing for a safety margin (5  106
20 g mouse, 2.5  1010 for 100 kg, 1.25  1010 for
50 kg).
Importantly, we demonstrate for the ﬁrst time
the feasibility of differentiating cirrhotic patients’
monocytes into functional macrophages comparable
to healthy volunteers in a GMP environment. This
gives hope that the ex vivo maturation of circulating
monocytes can be a technique to produce thera-
peutic mature macrophages for clinical cell therapy.
This paves the way for clinical studies in which
these macrophages are re-infused into cirrhotic pa-
tients with the aim of improving liver function and
ﬁbrosis. This would represent, if successful, a po-
tential signiﬁcant advance in cell therapy for liver
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